CRL vs MEDP: stock comparison and AI forecast
Charles River Laboratories International, Inc. (CRL) and Medpace Holdings, Inc. (MEDP) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CRL Charles River Laboratories International, Inc.
- Market Cap
- $16.80B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
MEDP Medpace Holdings, Inc.
- Market Cap
- $18.95B
- P/E Ratio
- 37.6x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- MEDP is 1.1 times larger than CRL by market capitalization ($18.95B against $16.80B).
- MEDP turns 18.2% of its revenue into net income, against -6.0% for CRL.
- MEDP carries 2.94 times debt per unit of equity, against 1.64 times for CRL.
- Both companies share the SEC industry classification Services-Commercial Physical & Biological Research.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CRL | MEDP |
|---|---|---|
| Market Cap | $16.80B | $18.95B |
| P/E Ratio | – | 37.60x |
| P/B Ratio | 5.92x | 32.40x |
| EPS | $-4.00 | $18.02 |
| Book Value/Share | $59.48 | $20.91 |
| Revenue/Share | $83.77 | $101.47 |
| FCF/Share | $7.76 | $23.87 |
Profitability & Margins
| Metric | CRL | MEDP |
|---|---|---|
| ROE | -8.4% | 88.5% |
| ROA | -3.2% | 22.5% |
| ROIC | 1.4% | 75.3% |
| Operating Margin | 2.2% | 21.4% |
| Net Margin | -6.0% | 18.2% |
| EBT Margin | -0.9% | 22.1% |
| Tax Rate | -152.4% | 17.4% |
Financial Health
| Metric | CRL | MEDP |
|---|---|---|
| Current Ratio | 1.35x | 0.83x |
| Quick Ratio | 1.04x | – |
| D/E Ratio | 1.64x | 2.94x |
| Financial Leverage | 2.65x | 3.94x |
| Interest Coverage | 5.0x | 733.2x |
| Working Capital | $394M | -$251M |
Cash Flow
| Metric | CRL | MEDP |
|---|---|---|
| Operating Cash Flow | $582M | $723M |
| Free Cash Flow | $371M | $668M |
| Capital Spending | -$212M | -$55M |
| OCF Growth YoY | -26.1% | 1.7% |
| FCF Growth YoY | -35.9% | -1.4% |
| FCF/Sales | 9.3% | 23.5% |
| CapEx/Sales | 5.3% | 1.9% |
Operational Efficiency
| Metric | CRL | MEDP |
|---|---|---|
| Asset Turnover | 0.53x | 1.23x |
| Receivables Turnover | 5.6x | 6.8x |
| Fixed Assets Turnover | 2.7x | 16.2x |
| Days Sales Outstanding | 65 days | 54 days |
Income Statement
| Metric | CRL | MEDP |
|---|---|---|
| Total Revenue | $4.00B | $2.84B |
| Operating Income | $90M | $607M |
| Net Income | -$238M | $518M |
| SG&A Expense | $762M | $193M |
Dividend & Shareholder Information
| Metric | CRL | MEDP |
|---|---|---|
| Shares Outstanding | 48M | 28M |
| Net Income Growth | – | 19.6% |
| EPS Growth | – | 26.0% |
CRL vs MEDP: stock comparison and AI forecast
Which is bigger, CRL or MEDP?
MEDP is 1.1 times larger than CRL by market capitalization ($18.95B against $16.80B).
Which one does Intratio's AI model rank higher, CRL or MEDP?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.